Physician profile
Eva Timbus
NPI 1457890774
$6,631.14
in general payments reported to CMS, 2019-2025
31 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,571 · 2022: $351 · 2023: $1,792 · 2024: $1,504 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,629 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,629.19 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $804.52 | 2023-2025 | Rybrevant, Carvykti, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $697.10 | 2021-2024 | Reblozyl |
| Seagen INC. | $456.05 | 2021-2023 | Adcetris, Padcev |
| Gilead Sciences, INC. | $400.36 | 2021-2025 | Trodelvy |
| Beigene USA, INC. | $330.00 | 2023-2024 | Brukinsa |
| Glaxosmithkline, LLC. | $261.06 | 2021-2024 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $257.47 | 2023-2024 | |
| Daiichi Sankyo INC. | $249.98 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $239.09 | 2021-2025 | |
| Amgen INC. | $229.15 | 2021-2023 | Nplate |
| Astrazeneca Pharmaceuticals Lp | $215.72 | 2024-2025 | Enhertu, Saphnelo |
| Regeneron Healthcare Solutions, INC. | $208.57 | 2023-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $208.12 | 2021-2025 | |
| Genzyme Corporation | $182.02 | 2021-2024 | |
| Syndax Pharmaceuticals, INC. | $149.88 | 2025 | Revuforj |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $145.03 | 2023 | |
| Genmab U.S., INC. | $124.99 | 2024 | Epkinly |
| Abbvie INC. | $124.99 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $124.99 | 2023 | Imbruvica |
| Kite Pharma, INC. | $122.06 | 2023 | Yescarta |
| Puma Biotechnology, INC. | $122.06 | 2021 | |
| Amag Pharmaceuticals, INC. | $122.06 | 2021 | |
| Merck Sharp & Dohme LLC | $120.03 | 2024-2025 | Keytruda |
| Sobi, INC | $119.04 | 2025 | |
| Stemline Therapeutics INC. | $103.48 | 2021 | |
| Adc Therapeutics America, INC. | $96.82 | 2021 | |
| Kyowa Kirin, INC. | $94.29 | 2021 | |
| Tg Therapeutics, INC. | $93.90 | 2025 | |
| Pharmaessentia USA Corporation | $84.89 | 2023 | Besremi |
| Legend Biotech USA INC. | $74.32 | 2023 | Carvykti |
| Agios Pharmaceuticals, INC. | $69.10 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Timbus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.